Levocabastine
From Wikipedia, the free encyclopedia
Levocabastine
|
|
Systematic (IUPAC) name | |
1-[4-cyano-4-(4-fluorophenyl)-cyclohexyl]- 3-methyl-4-phenyl-piperidine-4- carboxylic acid | |
Identifiers | |
CAS number | |
ATC code | R01 S01GX02 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C26H29FN2O2 |
Mol. mass | 420.519 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | 3 |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status |
℞ Prescription only |
Routes | Ophthalmic, intranasal |
Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis.
Levocabastine was discovered at Janssen Pharmaceutica in 1979.
[edit] References
- Pipkorn U, Bende M, Hedner J, Hedner T., A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis, Allergy. 1985 Oct;40(7):491-6.
- RxList (2004). Livostin Online, Description, Chemistry, Ingredients - Levocabastine. LIVOSTIN. RxList Inc. Retrieved on 9 October 2005.
- Novartis Pharmaceuticals (March 2002). LIVOSTIN (PDF). Retrieved on August 20, 2006.
- ^ RxMed: Pharmaceutical Information - LIVOSTIN NASAL SPRAY. Retrieved on 13 November 2005.
|